Scientists across the world are in a global race to discover a vaccine/therapeutic treatment that targets COVID-19 and, while this vitally important research continues at pace, even the most optimistic of experts believe we could be up to 18 months away from achieving a global solution.
What they do know so far is that the latest strain of Coronavirus is a highly contagious respiratory disease that reaches into your respiratory tract and certain groups of people are at far greater risk than others. This includes individuals who suffer from lung disorders, such as Chronic Obstructive Pulmonary Disease (COPD).
As described by the NHS, COPD is the name given to a group of lung conditions that cause breathing difficulties like emphysema (damage to the air sacs in the lungs) and chronic bronchitis (long-term inflammation of the airways).
The outlook for COPD varies from patient to patient, but the condition cannot be cured or reversed and can have a significant impact on the quality of life, with patients reliant on extra oxygen.
This additional requirement is delivered via tanks of compressed oxygen that are often heavy and require the patient to keep on top of the levels remaining to have them refilled. In today's current climate many COPD patients are quarantining due to Covid-19 and their high-risk factor and it’s more vital than ever that a different mode of oxygen delivery is found.
One solution to this problem is GCE’s Zen-O™, a portable oxygen concentrator, which takes air from the room and converts it into concentrated oxygen.
Weighing just 10.25lbs, the Zen-O™ offers lightweight portability and can deliver up to 2 litters of oxygen per minute in either pulse of continuous flow. It automatically responds to a patient’s breath rate, increasing the amount of oxygen dependent on the user’s movements and needs.
However, one of the biggest advantages of Zen-O™ isn’t its size and portability, it is the fact it is also a smart connected product.
PTC partner, InVMA, has developed an online platform for GCE Healthcare using PTC’s ThingWorx Industrial Innovation Platform.
Branded Clarity, the platform includes various partners working together to supply connectivity hardware, roaming SIM, and an additional layer of security to protect the patient.
Clarity enables Zen-O™ to be a smart product, giving it a secure online platform that allows home oxygen providers to view data, such as oxygen purity, device usage history, battery capability and activity.
Through remote monitoring, it is possible for predictive maintenance to be performed, a valuable service for high-risk groups keen to remain safe by minimizing external contract with people.
Zen-O™ and the deployment of ThingWorx underscores the value of rapid application development, connectivity and analytics capabilities in products. PTC is proud to be part of this group, helping to improve the quality of life for people everywhere, especially in this time of unprecedented uncertainty.